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Background: Epsilon is an antitoxin of the ε/ζ toxin-antitoxin (TA) system family, which is 
widespread in pathogenic bacteria. 
Results: In vitro and in vivo degradation of the Epsilon protein is shown. 
Conclusion: ClpXP protease is responsible for the degradation of the Epsilon antitoxin. 
Significance: The first demonstration of in vitro degradation of the antitoxin from Gram-positive 
bacteria. 
 
 
ABSTRACT 
Most bacterial genomes contain different 
types of toxin–antitoxin (TA) systems. The ω-
ε-ζ proteinaceous type II TA cassette from the 
streptococcal pSM19035 plasmid is a member 
of the ε/ζ family, which is commonly found in 
multiresistance plasmids and chromosomes of 
various human pathogens. Regulation of type 
II TA systems relies on the proteolysis of 
antitoxin proteins. Under normal conditions, 
the Epsilon antidote neutralizes the Zeta toxin 
through the formation of a tight complex. In 
this study, we show, using both in vivo and in 
vitro analyses, that the ClpXP protease is 
responsible for Epsilon antitoxin degradation. 
Using in vivo studies, we examined the 
stability of the plasmids with active or inactive 
ω-ε-ζ TA cassettes in B. subtilis mutants that 
were defective for different proteases. Using 
in vitro assays, the degradation of purified 
His6-Epsilon by the His6-LonBs, ClpPBs and 
ClpXBs proteases from B. subtilis was 
analyzed. Additionally, we showed that 
purified Zeta toxin protects the Epsilon 
protein from rapid ClpXP-catalyzed 
degradation. 
 
 
Toxin-antitoxin (TA) systems are widely 
found in plasmids and chromosomes of many 
bacteria, despite the fact that they are not 
essential for normal cell growth. Due to their role 
in the maintenance of mobile genetic elements 
and the response to specific stresses, the 
presence of TA systems seems advantageous for 
cell survival in the natural environment (1). In 
type II TA systems, where both components are 
proteins, the toxin is neutralized by direct 
interaction with the cognate antitoxin. These 
systems rely on the different decay rates of the 
two proteins that are involved, and the toxins are 
often much more stable than the antidotes. The 
genetic organization of TA operons ensures a 
higher transcription level of the antidote than the 
toxin genes, which results in the inactivation of 
the toxins. Regulation of type II TA systems, 
which relies on the proteolysis of antitoxin 
proteins, has been studied mainly in Escherichia 
coli. It has been shown that, in many cases, the 
unfolded nature of the antitoxin protein or its 
unstructured C-terminal domain is the cause of 
its vulnerability to degradation by intracellular 
proteases. In most cases, the Lon protease, which 
represents a major class of ATP-dependent 
proteases, is involved in antitoxin degradation 
(2–10). There are also known TA systems that 
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use the two-component protease ClpP, which 
cooperates with the ATPase–active chaperones 
ClpA or ClpX (11, 12). Moreover, degradation 
of the antidote can be carried out by more than 
one protease (12–15). In contrast to the E. coli 
antitoxins, knowledge of the proteolysis of 
antitoxins from other bacterial species is scarce. 
Until now, only Donegan et al. (16) had 
described this process in Gram-positive bacteria. 
These authors demonstrated that the MazEsa, 
Axe1, and Axe2 antitoxins from the three known 
TA systems in Staphylococcus aureus are rapidly 
degraded in vivo by the ClpCP protease. 
The ε/ζ TA family is commonly found 
on plasmids (17–20) and chromosomes of many 
human pathogens (21), including both Gram-
positive and Gram-negative bacteria (22, 23). 
Information concerning this TA family has been 
gathered from many years of studies on the ε/ζ 
system from the pSM19035 plasmid, which was 
originally isolated from the clinical strain of 
Streptococcus pyogenes (24) and was expanded 
by studies on the homologous PezAT system in 
Streptococcus pneumoniae (25, 26). The ω-ε-ζ 
cassette plays a major role in the stable 
inheritance of pSM19035 in Bacillus subtilis 
cells and acts as a post-segregational killing 
system (27, 28). An unusual feature of this 
system, which is located on a plasmid, is the lack 
of transcriptional regulation by the free antitoxin 
or the antitoxin in complex with the toxin. 
Autorepression is ensured by a third regulatory 
component, the Omega protein, which is a global 
regulator of other functions connected with 
plasmid replication and copy number control 
(29). The ω gene constitutes a transcriptional 
unit with the downstream ε and ζ genes, which 
are tightly regulated by the ω promoter. 
Interestingly, the ω gene also forms an atypical 
two-cistronic partition system together with the δ 
gene (30). 
The inactive ε2ζ2 complex forms a unique 
heterotetramer, with the two Epsilon proteins 
sandwiched between the Zeta monomers (31). 
Analysis of the two-hybrid interaction between 
the N-terminal part of Zeta and the N-terminal 
region of Epsilon showed that these regions are 
involved the formation of the ε2ζ2 complex (32). 
The estimated in vivo half-life of the Epsilon 
protein is ~18 min, whereas the half-life of Zeta 
is over 1 h (27). 
To identify the protease(s) responsible for 
the degradation of the antidote Epsilon protein, 
lon and clpX deficient mutants of B. subtilis were 
constructed and were used together with the 
clpP, clpC, clpE and codX mutants to test the 
maintenance of the shortened derivatives of the 
pSM19035 plasmid. The data indicate that the 
ClpXP protease is the enzyme involved in the 
degradation of the antidote Epsilon in growing B. 
subtilis cells. The His6-Epsilon antitoxin, the 
Zeta toxin and the His6-LonABs, ClpPBs and 
ClpXBs proteases were purified and used in in 
vitro degradation assays. Our in vitro proteolysis 
tests confirmed that ClpXP is the protease 
responsible for the degradation of the Epsilon 
antitoxin. 
 
EXPERIMENTAL PROCEDURES 
Bacterial strains, media and growth 
conditions–All bacterial strains and plasmids 
used in this study are listed in Table 1. 
Escherichia coli DH5α strain was used for 
plasmid construction. Bacteria were grown in 
Luria-Bertani (LB or LBA) or 2YT media (41) 
and in minimal SMM media (42) supplemented 
with the appropriate antibiotics at the following 
concentrations (μg ml-1): ampicillin (Ap), 100; 
spectinomycin (Spc), 60 or 100; erythromycin 
(Erm), 5; chloramphenicol (Cm), 30 for E. coli 
and 5 for B. subtilis; neomycin (Neo), 5; 
kanamycin (Km), 50; tetracycline (Tet), 10. 
Construction of B. subtilis lon and clpX 
mutants–To delete the chromosomal lon gene, 
the corresponding DNA fragment was generated 
by PCR and was cloned into the pTZ57R/T 
vector from the InsT/Aclone
TM
 PCR Product 
Cloning Kit. The oligonucleotides 5'-
TGGTTCATACTAAAGTCACGG-3' and 5'- 
GGTACTGTTCCGGTTTTACTGC-3' and the 
YB886 chromosomal DNA were used to amplify 
the lonA sequence. The EcoO109I/MunI internal 
fragment of the lonA sequence was then replaced 
with the SspI/PvuII DNA fragment of the pHP13 
vector that encompasses the cat gene. To 
construct the chromosomal deletion of the clpX 
gene, the corresponding DNA fragment was 
generated by PCR using the oligonucleotides 5'- 
GAATGTGCAAGTCAGAAAC-3' and 5'-
AGGTTTGTGCTTATC-3' and YB886 
chromosomal DNA. This blunted fragment, 
which was obtained with the Pfu DNA 
polymerase, was cloned into the pUC18 vector 
lacking of the MCS sequence between the PvuII 
sites. The SauI/MunI (both ends blunted) internal 
fragment of the clpX sequence was replaced with 
the SspI/PvuII DNA fragment of the pHP13 
vector that encompassed the cat gene. The 
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pTZ57R/TlonA::cat and pUC18clpX::cat 
plasmids were linearized at the unique ScaI 
restriction sites and used to transform YB886. 
Chloramphenicol resistant integrants (in lonA or 
clpX sequences) were verified by restriction 
analysis of the PCR products that were generated 
from their chromosomal DNA using 
oligonucleotides corresponding to the lonA or 
clpX sequences, respectively. 
DNA manipulations–Routine DNA 
recombinant techniques were performed as 
described in Sambrook et al. (41). Restriction 
enzymes and other enzymes were used according 
to the supplier's instructions. B. subtilis 
chromosomal DNA was isolated as described by 
Burdett et al. (43). E. coli transformation was 
performed using the standard calcium chloride 
method or by electrotransformation with a Gene-
Pulser (BioRad) according to the protocol 
described by Sambrook et al. (41). 
Electrotransformation of B. subtilis and 
protoplasts with plasmid DNA was performed as 
described by Bron (44), whereas the 
transformation of competent B. subtilis cells with 
chromosomal or ligated DNA was performed 
according to the protocol described by 
Rottländer and Trautner (45). 
Construction of plasmids for overproduction 
of proteins–The Fepsi (5'-
GCCGGATCCATGGCAGTTACGTATG-3') 
and Repsi (5'-
CTCGGATCCTTAAGCCACTTTCTCTTTATT
CAA-3') primers were used to amplify the 
epsilon gene from the pBT286 plasmid. The 
PCR product was digested with BamHI and was 
ligated into the BamHI site of the pET28a(+) 
plasmid (Novagen) for His6-Epsilon 
overproduction. The proper orientation of the 
inserted fragment was verified by PCR with the 
FT7 universal primer and the Repsi primer. The 
Fzeta (5'-
GGTGGTCATATGGCAAATATAGTCAATTT
TAC-3') and Rzeta (5'-
GGTGGTTGCTCTTCCGCAAATACCTGGAA
GTTTAGG-3') primers were used to amplify the 
zeta gene using the pBT286 plasmid as a 
template. The PCR product was cloned into the 
NdeI and SapI sites of the pTXB1 vector (New 
England Biolabs), creating the pTXB1zeta 
plasmid for the overproduction of Zeta toxin. 
The spx gene was amplified using the Fspx (5'-
GCGAATTCATGGTTACACTATACACATCA
-3') and Rspx (5'-
GCGTCGACTTAGTTTGCCAAACGCTGT-3') 
primers and YB886 chromosomal DNA. The 
PCR product was digested with EcoRI and SalI 
and was cloned into a similarly digested 
pET28a(+) plasmid. As a result, a plasmid 
overproducing the His6-Spx protein was 
obtained. The full-length lonA gene from 
B. subtilis YB886 was amplified using the Flon 
(5'-GCGAATTCATGGCAGAAGAATTAAAA-
3') and Rlon (5'-
GCGTCGACTCATTTCTTCTCTCCTAC-3') 
primers. The PCR product was cloned into the 
pET28a(+) plasmid at the EcoRI and SalI sites to 
create a plasmid for the overproduction of His6-
LonABs. The clpP and clpX genes from 
B. subtilis YB886 were amplified using the FclpP 
(5'-
GGTGGTCATATGAATTTAATACCTACAGT
C-3') and RclpP (5'-
GGTGGTTGCTCTTCCGCACTTTTTGTCTTC
TGTGTG-3') or the FclpX (5'-
GGTGGTCATATGTTTAAATTTAACGAGGA
A-3') and RclpX (5'-
GGTGGTTGCTCTTCCGCATGCAGATGTTT
TATCTTG-3') primers, respectively. The PCR 
products were digested with NdeI and SapI and 
were ligated into the NdeI and SapI sites of 
pTXB1, creating the pTXB1clpPBs and 
pTXB1clpXBs plasmids for the overproduction of 
ClpPBs or ClpXBs, respectively. 
Sequences of all cloned genes were verified by 
sequencing. 
Proteins purification–All proteins were 
overproduced in E. coli BL21 (DE3) cells. The 
His6-Epsilon, His6-Spx and His6- LonABs, N-
terminally hexa-histidine tagged proteins were 
purified using Ni-TED columns (Macherey-
Nagel), and the same purification procedure was 
used for these proteins. Overnight cultures were 
diluted 1:100 in 150 ml of LB supplemented 
with Km and were incubated at 37˚C with 
shaking. Protein expression was induced by the 
addition of 0.6 mM IPTG to the cultures at an 
OD660 of ~0.3, and the cultures were incubated 
for 3 h at 28˚C. The bacteria were then harvested 
and stored at -20˚C until use. Frozen cells were 
resuspended in 3 ml of phosphate-buffered saline 
(10 mM Na2HPO4, 1.8 mM KH2PO4, 140 mM 
NaCl, 2.7 mM KCl; pH 7.4) with 1 mg ml
-1 
lysozyme and were incubated on ice for 30 min, 
followed by lysis by sonication. All subsequent 
purification steps were performed under native 
conditions following the manufacturer’s 
instructions. Purified proteins were dialyzed 
against the storage buffer (16.18 mM Na2HPO4, 
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16.18 mM NaH2PO4, 0.1 mM EDTA, 10% 
glycerol). After dialysis, the His6-Epsilon and 
His6-Spx protein samples were centrifuged at 
4˚C at 7, 000 g for 3 min to remove the insoluble 
fraction. Purified proteins were stored in small 
aliquots at -80˚C. 
The IMPACT affinity tag system (New England 
Biolabs), which is a self-cleavable system, was 
used to purify the ClpXBs and ClpPBs proteins 
(46, 47), as well as the Zeta toxin (this work). 
ClpXBs was further purified from a HiTrap Q HP 
column (GE Healthcare) by elution with a 100-
600 mM KCl gradient. The fraction containing 
pure ClpXBs was concentrated using the Amicon 
filter device (Millipore). Purified ClpXBs and 
ClpPBs, which contained no extra residues, were 
dialyzed against the storage buffer (25 mM Tris 
pH 8, 100 mM KCl, 5 mM DTT, 1 mM MgCl2, 
50% glycerol) and were stored in aliquots at -
20˚C. To purify the Zeta protein, BL21 (DE3) 
cells harboring the pACE1 plasmid, which 
carries the epsilon gene, were transformed with 
the pTXB1zeta plasmid. Overnight cultures were 
diluted 1:100 in 800 ml of LB supplemented 
with Ap and Tet and were incubated at 37˚C with 
shaking until an OD660 of 0.4 was reached. After 
induction of zeta gene expression using 0.6 mM 
IPTG, the cells were incubated for an additional 
3 h at 28˚C; then, the cells were pelleted by 
centrifugation and stored at -20˚C until use. All 
subsequent purification steps were carried out at 
4˚C. The frozen cells were resuspended in 40 ml 
of buffer A (50 mM Tris-HCl pH 7.5, 10% 
glycerol) and were lysed by sonication. After 
centrifugation at 15,000 g for 30 min, the clear 
supernatant was incubated with 5 ml of chitin 
resin for 1 h with gentle shaking. Then, the chitin 
column was washed with 150 ml of buffer A and 
75 ml of buffer B (50 mM Tris-HCl pH 7.5, 150 
mM NaCl, 10% glycerol). Zeta protein was 
released from the chitin beads by overnight 
incubation with 10 ml of cleavage buffer 
containing thiol (buffer B with 50 mM DTT). 
The eluted Zeta protein, with no extra residues, 
was concentrated using an Amicon filter device 
(Millipore), dialyzed against the storage buffer 
(50 mM Tris-HCl pH 7.5, 50% glycerol) and 
stored at -20˚C. 
The purities of all the proteins were verified by 
SDS-PAGE with Coomassie blue staining. 
Protein concentrations were determined by 
comparing the intensity of the protein bands with 
that of the bovine serum albumin standard using 
Multi Gauge V3.0 software (FujiFilm). 
Plasmid stability assay–The apparent 
plasmid stability was determined as previously 
described (28). B. subtilis cells containing the 
tested plasmid were grown overnight at 30°C in 
liquid SMM medium supplemented with the 
appropriate antibiotics, including erythromycin 
and the proper chromosomal markers. The 
plasmid stability tests for the ΔclpP mutant were 
performed essentially in the same way, except 
that 2YT medium was used, and the growth 
cycle was 12 h to avoid the stationary phase of 
growth. 
Preparation of cell extracts–Cell extracts of 
B. subtilis YB886 and the B. subtilis protease 
mutants (ΔclpP, ΔclpX, ΔclpC, ΔclpE and 
ΔlonA) were prepared from 5 ml cultures of 
OD660 of 0.5−0.6. After centrifugation at 14,000 
g for 1 min, the cells were resuspended in 43 μl 
of PBS and were lysed by sonication. The 
insoluble material was removed by 
centrifugation at 5,000 g for 5 min at 4C. The 
supernatants were collected into new Eppendorf 
tubes and were kept on ice. 
His6-Epsilon stability in cell extracts of 
mutant strains–Five micrograms of His6-Epsilon 
protein was mixed with 3.5 μl of cell extracts in 
a final reaction volume of 15 μl and was 
incubated for 1 h at 37˚C. The samples were 
boiled at 99˚C for 5 min in 4x Laemmli buffer 
and were analyzed by SDS-PAGE, followed by 
Coomassie blue staining.  
In vitro proteolysis reactions–Catalysis by 
LonABs: Standard proteolysis reactions of 25 μl 
contained 0.5 μg of casein or various amounts of 
His6-Epsilon protein (0.115 μg, 0.27 μg, or 0.4 
μg) as a substrate and 0.5 μg of His6-LonABs 
protease in the reaction buffer (48) supplemented 
with an ATP-regenerating system (5 mM 
creatine phosphate, 0.05 μg μl-1 creatine kinase; 
Roche). The reactions were carried out for 2 h at 
32˚C and were terminated by the addition of 4x 
Laemmli buffer and incubation at 99˚C for 5 
min. The proteins were separated by SDS-PAGE 
using 14% Tris-tricine gels and were stained 
with Coomassie blue. 
Catalysis by ClpXPBs: In vitro degradation of 
the His6-Spx protein by purified ClpXPBs was 
performed in a reaction volume of 60 μl 
containing 2.56 μg of ClpXBs and 1.92 μg of 
ClpPBs pre-incubated in degradation buffer (49) 
for 7 min at 30˚C. Following the addition of 2.4 
μg of His6-Spx, the reaction was carried out at 
30˚C. At the indicated time intervals, 15 μl of the 
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reaction mixture was collected, treated with 4x 
Laemmli buffer and heated for 5 min at 99˚C. 
The in vitro degradation assay of purified 
His6-Epsilon was carried out in a reaction 
volume of 105 μl containing degradation buffer 
(49); 4.5 μg of the ClpXBs and 3.36 μg of the 
ClpPBs proteases were pre-incubated in the buffer 
for 7 min at 30˚C. Then, 5 μg of His6-Epsilon 
was added, and the reaction mixture was 
incubated at 30˚C. When indicated, His6-Epsilon 
was pre-incubated with 5 μg of Zeta protein. At 
the indicated time intervals, 15 μl of the reaction 
mixture was collected, treated with 4x Laemmli 
buffer and heated for 5 min at 99˚C. The 
collected samples were analyzed using 14% Tris-
tricine SDS-PAGE gels, followed by Coomassie 
blue staining. The levels of Epsilon protein were 
determined after proteolysis from three 
independent experiments using Multi Gauge 
V3.0 software (FujiFilm). The intensity of the 
Epsilon protein in the 0-min reaction was set to 
100%. 
Mass spectrometry–Peptides resulting from 
Epsilon protein digestion with protease ClpXP 
were analyzed by LC-MS-MS/MS (liquid 
chromatography coupled to tandem mass 
spectrometry) using Nano-Acquity (Waters) LC 
system and Orbitrap Velos Pro mass 
spectrometer (Thermo Electron Corp., San Jose, 
CA). Prior to the analysis, peptides were reduced 
with 100 mM DTT (for 30 minutes at 56°C), 
alkylated with 0.5 M iodoacetamide (45 minutes 
in darkroom at room temperature). Peptide 
mixture was applied to RP-18 precolumn 
(nanoACQUITY Symmetry® C18 – Waters 
186003514) using water containing 0,1% TFA as 
mobile phase and then transferred to nano-HPLC 
RP-18 column (nanoACQUITY BEH C18 - 
Waters 186003545) using an acetonitrile gradient 
(0% - 35% AcN in 160 minutes) in the presence 
of 0,1% formic acid with the flow rate of 300 
nl/min. Column outlet was directly coupled to 
the ion source of the spectrometer working in the 
regime of data dependent MS to MS/MS switch. 
A blank run ensuring lack of cross contamination 
from previous samples preceded each analysis. 
Acquired raw data were processed by Mascot 
Distiller followed by Mascot Search (Matrix 
Science, London, UK, on-site license) against 
SwissPROT database (20110124). Search 
parameters for precursor and product ions mass 
tolerance were 20 ppm and 50 mmu, 
respectively, enzyme specificity: none; missed 
cleavage sites allowed: 0; variable modification 
of methionine oxidation and cysteine 
carbamidomethylation. Peptides with Mascot 
Score exceeding the threshold value 
corresponding to < 5% False Positive Rate, 
calculated by Mascot procedure, and with the 
Mascot score above 30 were considered to be 
positively identified. Mascot results were 
analyzed by MScan – in house software (50). 
 
RESULTS 
Involvement of the ClpP protease in ω-ε-ζ 
addiction activity–The presence of the ω-ε-ζ 
gene cassette efficiently stabilizes plasmids in B. 
subtilis via postsegregational killing of the cells 
that have not received a copy of the plasmid 
(28). To determine the protease(s) involved in 
the degradation of the Epsilon antidote of the 
pSM19035 plasmid TA system, the stabilities of 
the pBT233-1 (containing an intact ω-ε-ζ 
operon) and pBT233-1S (containing a non-
functional Zeta toxin) plasmids were tested in 
B. subtilis mutants defective in different 
proteases. The pBT233-1 plasmid is a deletion 
derivative of the pSM19035 plasmid and 
contains a replication operon and the ω-ε-ζ 
stability gene operon, together with the 
erythromycin resistance determinant (39). It 
behaves in manner that is similar to the parental 
plasmid, except for an increased number of 
copies, which can reach up to 15 copies per cell 
(40). The pBT233-1S version differs from 
pBT233-1 only in the zeta gene sequence; a stop 
codon was created in the by pBT233-1S plasmid 
by filling in the SpeI restriction site (40). The 
resulting plasmid is unstable due to the non-
functionality of the Zeta protein, which is 
truncated after 79 amino acids. The B. subtilis 
mutant strains used in this study were separately 
transformed with the pBT233-1 and pBT233-1S 
plasmids that contain the erythromycin resistance 
that is conferred by derivatives of the pSM19035 
plasmid. Because the B. subtilis ΔclpP mutant 
QB4916 is deficient in DNA uptake (34), to 
obtain the proper strains, the plasmids containing 
YB886pBT233-1 and YB886pBT233-1S were 
transformed with chromosomal DNA from 
QB4916 (Table 1). All resultant strains were 
tested for plasmid stability as described in the 
Methods section. The wild-type YB886 strain 
carrying the pBT233-1 or pBT233-1S plasmid 
was used as a positive and negative control, 
respectively. To maintain the logarithmic phase 
of bacterial growth, the strains were grown in 
minimal SMM medium at a low temperature. 
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Because the ΔclpP mutation confers pleiotropic 
effects on the physiology of B. subtilis cells and 
prevents growth in minimal media by surviving 
in stationary phase (34), the stability tests for this 
mutant were performed using the rich 2YT 
medium with short periods between the 
subsequent culture dilutions. Comparison of the 
generational plasmid retention of the different 
strains is presented in Fig. 1A and shows that the 
B. subtilis lon mutants with both plasmids 
behave similar to the wild-type isogenic strain; 
the pBT233-1 plasmid was stably maintained for 
up to 100 generations, whereas the pBT233-1S 
plasmid was lost very quickly from the dividing 
bacterial cells. In contrast, the loss rate of both 
plasmids was essentially the same in the ΔclpP 
mutant, proving that the absence of the ClpP 
protease prevented Zeta toxin activity. These 
results indicate that ClpP, and not Lon, is 
involved in the functioning of the ω-ε-ζ 
addiction system. 
The ClpX ATPase is required for Epsilon 
antidote degradation–ClpP is an ATP-dependent 
protease. In contrast to the Lon protease, the 
proteases of the Clp family form complexes with 
different ATPases to promote protein 
degradation processes (51). Moreover, there is 
no competition between the different ATPases 
for the proteolytic ClpP subunits in B. subtilis, 
either under standard or stressed growth 
conditions (52). To define the ATPase subunit 
involved in the degradation of the Epsilon 
antidote, different B. subtilis mutants defective in 
one of these proteins were examined for the 
stability of the plasmid bearing the ω-ε-ζ operon. 
The strains deficient in ATPases, clpY (PS28), 
clpC (QB4756), clpE (QB8023) and clpX 
(YBX01), were transformed with the pBT233-1 
or pBT233-1S plasmids, and their stable 
maintenance under non-selective growth 
conditions was tested. Taking into account the 
requirement of clpC and clpX for growth at high 
temperatures (36, 53), the stability tests for all of 
the ATPase mutants were performed at 30ºC. 
The collective data for all of the ATPase mutants 
are presented in Fig. 1B. The stability of the 
pBT233-1 plasmid was affected only in the clpX 
defective strain, showing a loss rate similar to 
that of pBT233-1S, which does not produce an 
active Zeta toxin. These results indicate that 
ClpX is the ATPase subunit that cooperates with 
the catalytic ClpP protease to degrade Epsilon. 
Epsilon stability in cell extracts of the mutant 
strains–The stability of the purified His6-Epsilon 
was assayed after incubation for 1 h with lysates 
obtained from the B. subtilis protease-deficient 
strains, including the ΔclpP, ΔlonA and the 
ATPase deficient strains ΔclpX, ΔclpC and 
ΔclpE. Lysate from the wild-type B. subtilis 
YB886 cells was used as a control for this 
experiment. Figure 2 shows that the Epsilon 
protein was more stable only after incubation 
with lysate from the ClpP protease-deficient 
strain. This suggests the involvement of ClpP in 
antitoxin proteolysis. Incubation of Epsilon with 
lysates from the ClpX, ClpC and ClpE mutant 
strains resulted in the proteolysis of the antitoxin 
(Fig. 2). The degradation patterns of these lysates 
were similar to that observed with the wild-type 
strain lysate. The results presented in Fig. 2 show 
that the LonA protease is most likely not 
responsible for antitoxin proteolysis because the 
ΔlonA lysate resulted in the degradation of 
Epsilon at a rate similar to that of the wild-type 
strain. 
Rapid in vitro degradation of Epsilon by 
ClpXPBs–Our in vivo experiments strongly 
indicated that the ClpXPBs protease is involved in 
Epsilon degradation. To perform in vitro 
degradation analysis, we purified the B. subtilis 
protease: ClpPBs, ClpXBs and LonABs. We 
included the LonABs protease in the in vitro 
analysis because the genetic results obtained by 
Lioy et al. (54) suggested that the Epsilon 
antitoxin was not specifically degraded in the B. 
subtilis null lonA mutant strain and, to a minor 
extent, in null clpX cells. The proteolytic activity 
of the purified proteases was verified in reactions 
with specific substrates. Spx protein, which is a 
global transcription regulator in B. subtilis, was 
used in the control reaction with the ClpXPBs 
protease, as its in vitro proteolysis by ClpXPBs 
has previously been demonstrated (49). Purified 
ClpXPBs protease exhibited enzymatic activity 
against purified His6-Spx protein in the in vitro 
degradation assays. In contrast, incubation of 
His6-Spx in reaction buffer without protease did 
not affect Spx stability (Fig. 3E).  
Stability of the purified His6-Epsilon protein was 
verified following its incubation for 1 h at 4, 20, 
30 and 37˚C. As demonstrated in Fig. 3D, 
Epsilon degradation did not occur in the absence 
of additional proteins. The in vitro proteolysis 
assay of the His6-Epsilon protein in the presence 
of the ClpXPBs protease at 30˚C clearly showed 
His6-Epsilon degradation. His6-Epsilon decay 
was very fast since; after 15 min, only 6.7% of 
the His6-Epsilon protein remained intact (Fig. 
Epsilon antitoxin degradation by ClpXP protease 
 
 
 
 
7 
3A). The same results were obtained with the 
Epsilon protein lacking the His6 tag (data not 
shown). Epsilon degradation did not occur in the 
presence of either ClpP or ClpX alone (Fig. 3C). 
Therefore, the active ClpXP complex, which is 
composed of the protease and the chaperon 
subunits, is required for degradation to occur. 
Under normal growth conditions, Epsilon forms 
a tight tetrameric complex with Zeta, thus 
inhibiting its toxicity. We tested whether 
ClpXPBs degrades the Zeta-bound Epsilon. As 
shown in Fig. 3B, the presence of equal amounts 
of purified Zeta protein significantly reduced the 
rate of Epsilon degradation. During the first 10 
min, the gradual degradation of Epsilon was 
observed (up to ~20%), while further 
degradation of Epsilon proceeded very slowly. 
Even after prolonged incubation (up to 60 
minutes), approximately 40% of the Epsilon 
protein remained (data not shown). We verified 
that Zeta did not affect Spx degradation by 
ClpXPBs (data not shown). Therefore, the lack of 
rapid degradation of Epsilon in the presence of 
Zeta was a consequence of the TA complex 
formation. We did not observe any degradation 
of the Zeta protein by ClpXPBs (data not shown). 
To check, whether the ClpXP protease has 
preferable digestion sites, reaction sample after 5 
minutes incubation was directly measured by 
LC/MS. Database search identified protein 
Epsilon with high identity reaching 94% protein 
coverage. Mass spectrometry analysis revealed 
that protease intensively digests the protein, 
either without amino acid or sequence position 
preference, generating overlapping peptides and 
peptides often longer by one amino acid (Fig. 4). 
Despite changing the reaction conditions, 
including different buffer compositions or 
protein concentrations, no degradation of His6-
Epsilon occurred in the presence of the LonABs 
protease. At the same time, casein, which is a 
known substrate of the Lon protease, was 
degraded by 50% by the His6-LonABs protease 
after 2 h at 32˚C, proving that an active protease 
was used in the in vitro assays (Fig. 5). 
 
DISCUSSION 
The function of type II TA systems is 
regulated by the proteolysis of antitoxin proteins 
(55). Antitoxin vulnerability to degradation by 
cellular proteases constitutes the molecular basis 
of TA systems (56). Antitoxin proteolysis has 
been examined in many E. coli TA systems, 
generally only using in vivo analysis. In the cases 
of the RelB (57), CcdA (3), HipB (9) and Kis 
(58) antitoxins, this process has been further 
elucidated using in vitro degradation assays. 
Still, little is known in this field for bacteria 
other than E. coli. Although the ω-ε-ζ cassette 
from pSM19035 is one of the best-described TA 
systems in Gram-positive bacteria (28, 59), the 
specific protease responsible for Epsilon 
antitoxin degradation has thus far been unknown. 
As expected for the antitoxin proteins, Epsilon 
has a shorter in vivo half-life (~18 min) than the 
Zeta toxin (>60 min) (27). In vitro analysis 
showed the higher stability against urea-induced 
unfolding and the higher resistance against 
unspecific proteolytic degradation of the Epsilon 
antidote when compared to the Zeta toxin. 
Moreover, the Epsilon protein, unlike many 
other antitoxin proteins, does not have an 
unfolded structure that results in physiological 
instability, but is instead folded into a three-helix 
bundle (31).  
The data presented in this paper demonstrate 
that Epsilon is a substrate of the ClpXP protease, 
which was confirmed both in vivo and in vitro. In 
the B. subtilis ΔclpP mutant, an active ω-ε-ζ 
cassette did not stabilize the pBT233-1 plasmid, 
which was lost at a similar rate as the plasmid 
containing an inactive cassette. Both of these 
plasmids were no longer present in the tested 
cells after approximately 60 generations. This 
indicates that the ΔclpP mutant did not contain 
the protease necessary for the proper addiction 
function of the examined TA cassette. Lack of 
ClpP most likely resulted in a higher stability of 
the Epsilon protein; therefore, the toxin was 
effectively neutralized, even when the plasmid 
was lost. ClpP is a two-component protease, 
which requires an ATPase-active chaperone 
responsible for substrate recognition for proper 
activity, unfolding and translocation into the 
proteolytic chamber. In Gram-positive bacteria, 
the chaperones ClpX, ClpC, ClpE and ClpY 
interact with the ClpP protease core. In a 
previous paper, the ClpC chaperone was shown 
to be essential for the ClpP-mediated degradation 
of the MazEsa, Axe1, and Axe2 antitoxins in 
S. aureus, a Gram-positive human pathogen (16). 
Increased stability of these antitoxins was 
observed only in S. aureus strains that were 
deficient for clpC or clpP. Until now, this was 
the first and only publication concerning the 
degradation of antitoxin in Gram-positive 
bacteria.  
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We found that the ClpX chaperone, together 
with ClpP, contributes to the degradation of the 
streptococcal antitoxin Epsilon. In contrast with 
the clpX mutant, the pBT233-1 plasmid was 
stably maintained in the ClpE, ClpC, and ClpY 
deficient strains, suggesting that these 
chaperones are dispensable for Epsilon 
proteolysis. The lack of good quality anti-
Epsilon antibodies precluded the verification of 
Epsilon stability in the protease mutant strains by 
western blot analysis. Therefore, we attempted to 
indirectly verify the antitoxin stability by 
incubating purified His6-Epsilon with a total pool 
of proteins obtained from protease-deficient 
strains. Although a higher stability of the Epsilon 
protein was observed following incubation with 
a lysate lacking the ClpP protease, Epsilon 
proteolysis was observed in all of the tested 
extracts probably due to non-specific 
degradation. Therefore, this analysis did not 
result in the identification of the chaperone that 
cooperates with ClpP during Epsilon 
degradation.  
In vitro proteolysis assays confirmed our in 
vivo findings that the ClpXP protease was 
involved in Epsilon degradation. A drastic, rapid 
reduction in the antitoxin level was observed; the 
major degradation of Epsilon occurred in less 
than 15 min. We estimated that Epsilon is 
degraded by ClpXP with a T1/2 of ~8 min in 
vitro, which is similar to the degradation of Kis 
antitoxin by the ClpAP protease in in vitro 
proteolysis assays (58).  
In a TA complex, the toxin remains inactive 
due to its direct interaction with the antidote. The 
stability of the antitoxin protein increases due to 
structural changes that bring the disordered 
structure into order upon toxin binding (11, 60). 
When the unfolded domain does not adopt an 
ordered structure, the toxin blocks the access of 
the protease to the antitoxin by partial shielding 
the C-terminal fragment of the antitoxin from the 
solvent (61). Although the Epsilon antidote does 
not have a disordered structure or unfolded C-
terminal domain, its rapid degradation was 
observed in the presence of the ClpXP protease. 
As expected, the presence of the Zeta toxin in the 
in vitro degradation assay stabilized Epsilon, 
most likely as a result of complex formation 
between these two proteins. The conditions used 
in our in vitro experiments enabled the formation 
of stable ε2ζ2 complex, as it was previously 
shown (27) that the ε2ζ2 complex is stable 
between pH 5 and 9 and in high salt (2 M). 
However, it is possible that some ε and ζ 
molecules remained unbound in our in vitro 
assay. Therefore, the decrease in Epsilon 
quantity observed during the first 10 min most 
likely reflects the presence of free antitoxin 
molecules. In heterotetramer ε2ζ2, in which two 
molecules of the Epsilon protein are surrounded 
by two monomers of the Zeta protein, Zeta 
protects Epsilon from the ClpXP protease.  
Lioy et al. (54) reported that LonA is the 
putative protease responsible for the degradation 
of the Epsilon antidote, but the presented data 
were inconsistent and unconvincing. This was 
inferred from the plating efficiency of the B. 
subtilis ΔclpC, ΔclpX, ΔclpE, ΔclpP or ΔlonA 
cells that contained plasmids expressing the ω-ε-
ζ genes upon exposure to 50 µg ml-1 rifampicin 
because no reduction in the plating efficiency 
was observed for the ΔlonA cells. The plating 
efficiency of the ΔclpX showed an intermediate 
phenotype, which in our opinion is inexplicable 
due to the lack of any effect in the ΔclpP strain. 
Furthermore, the known pleiotropic effects of 
ΔclpP deletion on the B. subtilis phenotype (34) 
preclude the rational evaluation of the 
consequences of specific factors, such as Zeta 
toxin activity in this case. Although the authors 
mentioned that the level of Epsilon protein in the 
ΔlonA strain remained constant during the first 
120 min, concrete data unfortunately were not 
shown. In our study, the involvement of the Lon 
protease in Epsilon degradation was excluded by 
three different methods. The results of the 
plasmid stability tests, incubation of the purified 
Epsilon protein with lysate depleted of Lon 
protease, and the in vitro degradation assay 
clearly showed that the LonA protease does not 
play any role in the regulation of the ω-ε-ζ TA 
system in B. subtilis.  
It was previously shown that the efficiency 
of the ω-ε-ζ cassette differs in Gram-positive 
bacteria with a low DNA G/C content (40). The 
observed results did not depend on the plasmid 
copy number, but were most likely connected to 
the host-dependent cellular factors. One reason 
for this could be a different proteolytic regulation 
of this TA system. It was demonstrated for the 
mazEF system that homologous antidotes were 
degraded by various proteases in the host strains 
(12, 16), which were also dependent on 
environmental conditions (13). 
The hypothesis concerning the differences in 
the functioning of the TA systems in various 
bacteria and their proteolytic regulation could be 
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verified by similar studies with protease mutant 
strains or in vitro degradation analyses. The 
gained knowledge might be applied to the 
development of new strategies for coping with 
pathogens containing TA systems. 
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FIGURE LEGENDS 
FIGURE 1. Plasmid maintenance in the B. subtilis mutant strains. (A) Plasmid maintenance in the 
protease-deficient strains. The curves represent plasmid retention during growth without selection 
pressure. Continuous lines with filled symbols show the pBT233-1 plasmid, and the dashed lines with 
open symbols represent the pBT233-1S plasmid; YB886 (wt; ▲,Δ), QB4916 (clpP; ●,○), YBL01 
(lonA; ■,□). (B) Plasmid maintenance in the ATPase deficient strains. The curves represent plasmid 
retention during growth without selection pressure. Lines with circles show the data for the clpX 
mutant YBX01 carrying the pBT233-1 (●) or the pBT233-1S (○) plasmid. The thick continuous lines 
represent the QB4756 (clpC), QB8023 (clpE) and PS28 (codX) deletion strains carrying the pBT233-1 
plasmid, and the dashed lines with open symbols represent the maintenance of the pBT233-1S plasmid 
in QB4756 (Δ), QB8023 (□) and PS28 (◊). 
 
FIGURE 2. Epsilon stability in cell extracts of the mutant strains. SDS–PAGE gel stained with 
Coomassie blue. Five micrograms of purified His6-Epsilon was incubated for 1 h at 37˚C with lysates 
from the B. subtilis protease-deficient strains, including the ΔclpP and ΔlonA strains and the ATPase 
deficient strains ΔclpX, ΔclpC, and ΔclpE. Control: lysate from the wild-type B. subtilis. Protein mass 
ladder: Multicolor Low Range (Fermentas). 
 
FIGURE 3. In vitro degradation of the Epsilon antidote by ClpXPBs. (A) Time-course degradation of 
His6-Epsilon. ClpXBs (4.5 μg) and 3.36 μg of ClpPBs were pre-incubated in buffer for 7 min at 30˚C. 
Then, 5 μg of His6-Epsilon was added to the reaction mixture and incubated at 30˚C. At the indicated 
time intervals, 15 μl of the samples was collected and subjected to SDS-PAGE and Coomassie blue 
staining. The data shown on the corresponding graph are the averages of three independent 
experiments, and the standard deviation is also shown. (B) Time-course degradation of His6-Epsilon in 
the presence of purified Zeta toxin. Five micrograms of His6-Epsilon was pre-incubated with 5 μg of 
purified Zeta toxin for 7-10 min at 30˚C and was then added to the reaction mixture containing the 
ClpXPBs protease. At the indicated time intervals, 15 μl of the samples was collected and subjected to 
SDS-PAGE and Coomassie blue staining. The data shown on the corresponding graph are the 
averages of three independent experiments, and the standard deviation is also shown. (C) Epsilon 
degradation in presence/absence of the ClpPBs or ClpXBs protease subunits. The reaction conditions 
were the same as in A. (D) Stability of purified His6-Epsilon (1.5 µg) incubated for 1 h at different 
temperatures. Protein mass ladder (in C and D): Multicolor Low Range (Fermentas). (E) Time-course 
degradation of His6-Spx by ClpXPBs. ClpXBs (2.56 μg) and 1.92 μg of ClpPBs were pre-incubated in 
buffer for 7 min at 30˚C, and 2.4 μg of His6-Spx was then added to the reaction mixture and incubated 
at 30˚C. At the indicated time intervals, 15 μl of the samples was collected and subjected to SDS-
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PAGE and Coomassie blue staining. Control: His6-Spx protein incubated in the presence of reaction 
buffer for 60 min at 30˚C. CK is the creatine kinase from the ATP-regenerating system. 
 
FIGURE 4. LC/MS analysis of protein Epsilon after ClpXP protease degradation. Table represents 
list of identified peptides and respective Mascot Score. For clarity, duplicate peptides were removed. 
The same data are presented as percentages of peptides with certain C-terminus amino acid. Protease 
preferably hydrolyzes peptide bond following leucine and asparagine residues. This tendency however 
is not very specific, as other sites are also cleaved.  
 
 
FIGURE 5. In vitro degradation assay catalyzed by LonABs. Casein (0.5 μg) or various amounts of 
Epsilon (0.115, 0.27 or 0.4 μg) were incubated with 0.5 μg of His6-LonABs protease at 32˚C for 2 h.; 
60% of the reaction volume was loaded onto the gel. Protein mass ladder: Multicolor Low Range 
(Fermentas). CK is the creatine kinase from the ATP-regenerating system. 
 
 
 
 
TABLE 1. Bacterial strains and plasmids used in this study. 
 
Strain or plasmid Relevant characteristics Source  
or reference 
Strains   
        B. subtilis   
YB886 trpC2 metB5 xin-1 attSP amyE 33 
QB4916 trpC2 ∆clpP::spc 34 
PS28 trpC2 unkU::spc ∆codX 35 
QB4756 ∆mecB::spc 36 
QB8023 ∆clpE::spc T. Msadek 
YBX01 YB886 ∆clpX::cat this work 
YBL01 YB886 ∆lonA::cat this work 
        E. coli   
DH5 recA1endA1 gyrA96 thi1 hsdR17 (r
-
k m
-
k) supE44 relA1 deoR 
F
-
(Φ80 lacZΔM15) Δlac(ZYA-argF)U169 
37 
BL21(DE3) F-, ompT hsdSB (rB-mB-) gal dcm (λDE3) Novagen 
Plasmids   
pUC18 cloning vector, Ap
R
 Pharmacia 
pHP13 shuttle vector, Er
R  
Cm
R
 38 
pTZ57R/T PCR cloning vector Fermentas 
pBT286 source of ω, ε and ζ genes sequences for PCR amplification 28 
pBT233-1 derivative of pSM19035 containing ω-ε-ζ genes, ErR 39 
pBT233-1S derivative of pBT233-1; filling in of SpeI restriction site (pos. 
7116 according to EMBL X64695) resulting in truncation of 
ζ ORF, ErR 
40 
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pACE 1 the EcoRI-XmnI fragment of pBT286 (pos. 5666-6950 
encompassing the ω-ε genes); ligated to EcoRI-ScaI sites of 
pACYC184 vector 
28 
pET28a(+) E. coli expression vector, Km
R
 Novagen 
pTXB1 E. coli expression vector, Ap
R
 New Biolabs 
England 
pET28epsilon plasmid for overexpression of Epsilon antitoxin, Km
R
 this work 
pET28spx plasmid for overexpression of Spx protein, Km
R
 this work 
pET28lonABs plasmid for overexpression of LonA Bs protease, Km
R
 this work 
pTXB1zeta plasmid for overexpression of Zeta toxin, Ap
R
 this work 
pTXB1clpPBs plasmid for overexpression of ClpPBs protease, Ap
R
 this work 
pTXB1clpXBs plasmid for overexpression of ClpXBs chaperone, Ap
R
 this work 
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Figure 2 
 
 
 
 
 
 
 
 
 
Figure 3 
 
 
 
 
 
Epsilon antitoxin degradation by ClpXP protease 
 
 
 
 
16 
Figure 4 
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Figure 5 
 
 
 
 
 
 
 
